BECN1 and polycystic ovary syndrome: AS-IV treatment increased the expression of LC3-II/I and Beclin1 and decreased that of p62 in the rat ovarian tissues (compared with PCOS group, P<0.01 and P<0.001; compared with +AS-IV 20 mg/kg group, P<0.01 and P<0.001; compared with +AS-IV 40 mg/kg group, P<0.001) (Figure 3A).